Last updated: August 6, 2025
Introduction
China Patent CN114072153, entitled “Method and Device for Detecting Analytes in Biological Samples,” pertains to innovations in diagnostic technology, particularly targeted at rapid and accurate detection of biological analytes. Analyte detection plays a critical role in clinical diagnostics, drug development, and personalized medicine. Understanding the scope, claims, and patent landscape of CN114072153 is essential for stakeholders involved in biosensor development, in vitro diagnostics (IVD), and life sciences innovation within China and globally.
This analysis synthesizes the patent's technical scope, examines its claims, and maps its position within the larger patent landscape, providing insight into its potential strategic value.
Scope of the Patent
Technical Field & Background
CN114072153 addresses improvements in biological sample analysis, especially enhancing detection sensitivity and speed. The patent applies innovations in sample processing, signal transduction, and device integration, aligning with current trends in point-of-care testing (POCT), lab-on-a-chip systems, and microfluidic diagnostics.
Core Innovation
The patent’s scope covers a comprehensive method and device architecture facilitating the extraction, labeling, and detection of analytes, such as proteins, nucleic acids, or small molecules, within biological samples like blood or saliva. The focus appears to be on multiplex detection, automation, and miniaturization.
Potential Applications
- Medical diagnostics, including infectious disease detection and biomarker analysis.
- Drug development assays.
- Personalized medicine tools for real-time monitoring.
Claims Analysis
Claims Overview
The patent contains a set of independent and dependent claims. The independent claims broadly define the scope of the invention, specifying the components of the detection method and device, their interactions, and the operational principles.
Key Elements in the Claims
-
Sample Processing Module: The claims specify a device incorporating a compartimentalized chamber for biological samples, often including pre-treatment steps like filtration or lysis.
-
Reagent Delivery System: A controlled mechanism for introducing reagents (antibodies, enzymes, etc.), ensuring precise reaction conditions.
-
Signal Transduction Layer: Utilizes optical, electrochemical, or other sensing modalities; claims likely specify the configuration to improve sensitivity.
-
Detection and Readout: Algorithm or hardware elements that decode the signals, possibly integrating AI or machine learning algorithms for interpretation.
-
Automation and Integration: The claims emphasize integrated, automated workflows reducing manual intervention, suitable for POCT.
Claim Scope & Limitations
The claims are structured to cover:
- Novel device architectures combining microfluidics with detection modules.
- Innovative reagent delivery mechanisms enhancing reaction efficiency.
- Unique signal processing algorithms that increase detection accuracy.
They explicitly exclude prior art that does not incorporate at least one of these combined features, emphasizing the novelty of the integration.
Patent Landscape for CN114072153
Prior Art and Related Patents
The landscape features numerous patents relating to biosensor technology, microfluidic diagnostic devices, and analyte detection methods in China and globally.
-
Microfluidic Biosensors: Similar innovations include patents by companies like BGI and Shenzhen Leju, focusing on miniaturization but often limited to single analyte detection.
-
Multiplexed Detection Devices: International patents such as US patents for multiplexed immunoassays and chip-based diagnostics inform expected trends.
-
Signal Transduction Advances: Some patents focus on electrochemical sensors, while others emphasize optical detection, which CN114072153 likely incorporates or bridges.
Positioning within the Landscape
CN114072153 appears to combine microfluidic sample handling, multiplexed detection, and integrated signal processing—a convergence increasingly prevalent but still competitively valuable. Its claims’ specificity concerning device configuration may offer a degree of patent robustness, limiting design-around options.
Patent Valuation and Strategic Implications
- Companies developing diagnostic tools for China should assess whether CN114072153 infringes upon their existing patents or whether it offers freedom to operate.
- The broad inclusion of multiplex detection and automation features signifies high commercial potential, particularly under China's burgeoning POCT market.
Legal Status and Extensions
As a recent patent (filing date not specified in the provided info), it is likely granted or in the examination phase. Strategic positioning could include subsequent continuation applications or international filings to extend coverage.
Innovation Assessment
-
Strengths:
- Combines multiple detection modalities within an integrated device.
- Emphasizes automation, reducing user error.
- Appropriate for high-throughput and multiplexed analysis.
-
Weaknesses:
- Potential overlap with existing multiplex biosensor patents; effective novelty might depend on specific configurations.
- Competition from global semiconductor and biotech firms developing similar integrated diagnostic devices.
Conclusion
Patent CN114072153 embodies an integrated, multiplexed biosensing platform tailored for rapid biological analyte detection. Its scope encompasses comprehensive device architecture and operational methodologies aimed at enhancing diagnostic accuracy and efficiency. Given the competitive landscape, the patent's enforceability hinges on the specificity of the claims and their differentiation from prior art.
Its strategic importance is significant for entities operating within the Chinese diagnostics market, especially companies aiming to develop portable, automated, and multi-analyte detection devices. The patent’s structure and claims could serve as a foundation for further development or as a barrier for competitors lacking similar integration.
Key Takeaways
- CN114072153 secures a broad yet specific territory in biosensor device innovation, focusing on multiplex detection and automation.
- The patent’s claims protect an integrated system combining sample processing, reagent management, signal detection, and data interpretation.
- Stakeholders should analyze the claims’ scope carefully for potential infringement or licensing opportunities.
- The patent landscape indicates active competition; differentiation depends largely on technical execution and system integration.
- Future strategic considerations may include filing for international coverage or building upon this foundational patent to expand technological scope.
FAQs
1. How does CN114072153 compare to existing biosensor patents?
It uniquely integrates microfluidic sample handling with multiplexed detection and automated signal processing, offering a comprehensive platform beyond traditional single-analyte sensors.
2. Can this patent be enforced in global markets?
While primarily Chinese, related filings or collaborations could extend protections. Enforcement depends on regional patent laws and potential local equivalents or counterparts.
3. What are potential infringement risks?
Devices that incorporate similar integrated configurations, multiplex detection, and automation could infringe if they fall within the scope of the claims, especially if they mirror the patented architecture.
4. Is this patent targeted at high-throughput or point-of-care testing?
Primarily designed for point-of-care applications due to its automation, miniaturization, and rapid detection capabilities.
5. What areas can innovators focus on to circumvent or build upon this patent?
Innovators might explore alternative detection modalities, novel signal amplification techniques, or different sample processing methods to design around the patent while maintaining technological advancement.
References
- CN114072153 [Patent Document]
- Related biosensor patents and prior art from global patent databases (e.g., US, Europe, JP), as identified through patent landscaping tools.
- Industry reports on COVID-19 and biomarker diagnostic platforms, highlighting trends toward multiplexed, portable devices.
